GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Emcure Pharmaceuticals Ltd (BOM:544210) » Definitions » EV-to-FCF

Emcure Pharmaceuticals (BOM:544210) EV-to-FCF : 47.33 (As of Dec. 15, 2024)


View and export this data going back to 2024. Start your Free Trial

What is Emcure Pharmaceuticals EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Emcure Pharmaceuticals's Enterprise Value is ₹266,055 Mil. Emcure Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was ₹5,621 Mil. Therefore, Emcure Pharmaceuticals's EV-to-FCF for today is 47.33.

The historical rank and industry rank for Emcure Pharmaceuticals's EV-to-FCF or its related term are showing as below:

BOM:544210' s EV-to-FCF Range Over the Past 10 Years
Min: 31.37   Med: 33.99   Max: 47.33
Current: 47.33

During the past 4 years, the highest EV-to-FCF of Emcure Pharmaceuticals was 47.33. The lowest was 31.37. And the median was 33.99.

BOM:544210's EV-to-FCF is ranked worse than
70.91% of 550 companies
in the Drug Manufacturers industry
Industry Median: 25.795 vs BOM:544210: 47.33

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-12-15), Emcure Pharmaceuticals's stock price is ₹1359.25. Emcure Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was ₹30.976. Therefore, Emcure Pharmaceuticals's PE Ratio (TTM) for today is 43.88.


Emcure Pharmaceuticals EV-to-FCF Historical Data

The historical data trend for Emcure Pharmaceuticals's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Emcure Pharmaceuticals EV-to-FCF Chart

Emcure Pharmaceuticals Annual Data
Trend Mar21 Mar22 Mar23 Mar24
EV-to-FCF
- - - -

Emcure Pharmaceuticals Semi-Annual Data
Mar21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
EV-to-FCF Get a 7-Day Free Trial - - - - -

Competitive Comparison of Emcure Pharmaceuticals's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Emcure Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Emcure Pharmaceuticals's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Emcure Pharmaceuticals's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Emcure Pharmaceuticals's EV-to-FCF falls into.



Emcure Pharmaceuticals EV-to-FCF Calculation

Emcure Pharmaceuticals's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=266054.988/5620.97
=47.33

Emcure Pharmaceuticals's current Enterprise Value is ₹266,055 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Emcure Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was ₹5,621 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Emcure Pharmaceuticals  (BOM:544210) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Emcure Pharmaceuticals's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1359.25/30.976
=43.88

Emcure Pharmaceuticals's share price for today is ₹1359.25.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Emcure Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was ₹30.976.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Emcure Pharmaceuticals EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Emcure Pharmaceuticals's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Emcure Pharmaceuticals Business Description

Comparable Companies
Traded in Other Exchanges
Address
Plot No. P-1 and P-2, IT-BT Park, Phase II, M.I.D.C., Hinjawadi, Hinjawadi, MH, IND, 411057
Emcure Pharmaceuticals Ltd an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a range of pharmaceutical products across several therapeutic areas. Its portfolio includes orals including solids, liquid orals and dry syrup/suspensions., injectables such as vials and pre-filled syringes, and forms such as lyophilized & liquid and biotherapeutics.

Emcure Pharmaceuticals Headlines

No Headlines